CRISPR Market worth $6.12 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global CRISPR market to grow from USD 3.48 billion in 2026 to USD 6.12 billion by 2031, a 12.0% CAGR. North America represented 49.7% of the market in 2025, while products accounted for 70.7%; the report cites expanding research and therapeutic applications as growth drivers. It also notes Tune Therapeutics raised USD 175 million in Series B funding in January 2025 and Agilent acquired BioVectra for USD 925 million in July 2024.

Analysis

The report is a weak earnings signal, not a near-term catalyst: a third-party market forecast does not establish incremental revenue, share gains, or margin capture for any named company. Its market definition also spans research tools, services, and therapeutic development—economically different pools—so the headline growth rate should not be applied to any one issuer.

Over 1–3 months, the key test is company-level evidence: CRISPR-related product growth, order trends, or guidance from diversified suppliers such as Thermo Fisher Scientific (TMO), Agilent Technologies (A), Merck KGaA (MRK), and Lonza (LONN). Even if adoption grows, standardized kits and enzymes may face pricing pressure; differentiated editing reagents, screening workflows, and specialized services have a better chance of retaining value. Agilent’s historical BioVectra acquisition is not new upside from this report, and the article provides no incremental deal economics.

Over 6–18 months, next-generation editing could shift spend away from commodity Cas9 workflows toward more specialized reagents and services—but delivery, reproducibility, and clinical translation remain gating risks. Caribou Biosciences (CRBU) is a therapeutic developer, not a straightforward proxy for research-tool demand; the market forecast does not validate its pipeline or financing outlook. Contrarian view: the apparent growth opportunity may be real while the investable earnings impact for large suppliers remains immaterial, and competition can absorb growth through lower prices. No trade is justified on this release alone.

Key Decisions for Investors

• Do not trade the market-size forecast as an earnings revision. Treat TMO, A, MRK, and LONN as watchlist names until company disclosures identify CRISPR-linked revenue, growth, and margin contribution.
• At the next results and guidance updates, monitor consumables orders, life-science tools growth, and any commentary on editing kits, screening, or custom services. A sustained acceleration alongside stable pricing would strengthen the supplier thesis; flat growth or discounting would falsify it.
• Avoid using CRBU as a proxy for CRISPR tools adoption. Reassess only against its own clinical, financing, and pipeline catalysts; this report supplies no new evidence on those variables.
• Revisit the theme over 6–18 months if adoption demonstrably shifts toward specialized editing or services. Verify customer uptake, repeat purchasing, and competitive pricing before considering a supplier long; absent that evidence, no position.